LOC107986626: A Potential Drug Target and Biomarker (G107986626)
LOC107986626: A Potential Drug Target and Biomarker
LOC107986626 is a protein that is expressed in various tissues of the body, including the brain, heart, and blood vessels. It is a member of the integrin alpha-2 chain, which is a subunit of the plasmin system that plays a role in blood clotting and other cellular processes. LOC107986626 has been identified as a potential drug target or biomarker due to its unique expression pattern and its involvement in several cellular processes.
The Plasmin System
Plasmin is a protein that is involved in the degradation of damaged blood vessels and other cellular structures. It is a complex protein that consists of several subunits that are encoded by different genes. The integrin alpha-2 chain is one of the subunits of the plasmin system that is involved in the interaction between the plasmin protein and the cell surface.
LOC107986626 is a gene that encodes for a protein with a molecular weight of approximately 120 kDa. It is expressed in various tissues of the body, including the brain, heart, and blood vessels. The expression of LOC107986626 is highly dependent on the plasmin system, which suggests that it is involved in the plasmin response to various stimuli.
LOC107986626 as a Drug Target
The plasmin system has been identified as a potential drug target due to its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The integration of LOC107986626 into the plasmin system makes it a promising target for small molecules that can modulate the activity of the plasmin system.
One of the potential benefits of targeting LOC107986626 is its involvement in blood clotting, which is a critical mechanism for maintaining blood flow to the body's tissues. Plasmin is involved in the degradation of damaged blood vessels, which can lead to blood clots that can cause serious health problems if not treated promptly and effectively. Targeting LOC107986626 could potentially lead to the development of new treatments for blood clots and other cardiovascular diseases.
Another potential benefit of targeting LOC107986626 is its role in cancer progression. Plasmin is involved in the regulation of cell division, which is a critical factor in cancer growth and progression. LOC107986626 has been shown to be involved in the regulation of cell division in various cancer types, which suggests that it may play a role in cancer development. Targeting LOC107986626 could potentially lead to the development of new treatments for cancer.
LOC107986626 as a Biomarker
LOC107986626 has also been identified as a potential biomarker for several diseases. The expression of LOC107986626 has been shown to be involved in the regulation of cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.
For example, LOC107986626 has been shown to be involved in the regulation of cell division in various cancer types. Several studies have shown that LOC107986626 is involved in the regulation of cell division in breast, ovarian, and colorectal cancer. This suggests that LOC107986626 may be a useful biomarker for the development
Protein Name: Uncharacterized LOC107986626
The "LOC107986626 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC107986626 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC107986636 | LOC107986649 | LOC107986666 | LOC107986764 | LOC107986766 | LOC107986770 | LOC107986771 | LOC107986772 | LOC107986774 | LOC107986776 | LOC107986777 | LOC107986781 | LOC107986787 | LOC107986800 | LOC107986816 | LOC107986820 | LOC107986836 | LOC107986844 | LOC107986873 | LOC107986892 | LOC107986894 | LOC107986901 | LOC107986903 | LOC107986927 | LOC107986930 | LOC107986952 | LOC107986961 | LOC107986983 | LOC107986996 | LOC107987026 | LOC107987045 | LOC107987049 | LOC107987053 | LOC107987057 | LOC107987064 | LOC107987087 | LOC107987099 | LOC107987121 | LOC107987164 | LOC107987178 | LOC107987211 | LOC107987243 | LOC107987249 | LOC107987251 | LOC107987282 | LOC107987285 | LOC107987299 | LOC107987301 | LOC107987304 | LOC107987407 | LOC107987412 | LOC107987429 | LOC107987435 | LOC107987440 | LOC107987443 | LOC107987449 | LOC107987453 | LOC107987459 | LOC112267867 | LOC112267881 | LOC112267902 | LOC112267956 | LOC112267962 | LOC112267968 | LOC112267978 | LOC112268051 | LOC112268136 | LOC112268248 | LOC112268286 | LOC112268294 | LOC112268416 | LOC114224 | LOC123862 | LOC124901339 | LOC126987 | LOC129026 | LOC132386 | LOC143666 | LOC145474 | LOC145845 | LOC148430 | LOC148696 | LOC149351 | LOC149684 | LOC151760 | LOC153893 | LOC153910 | LOC154449 | LOC154761 | LOC155060 | LOC157273 | LOC158434 | LOC158435 | LOC158696 | LOC162137 | LOC202181 | LOC221946 | LOC254896 | LOC260339 | LOC283028
